Search results

763 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Clinical guidelines Remove Clinical guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Public health guidelines Remove Public health guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter

Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

Proposed [GID-TA10552] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]

Proposed [GID-TA10691] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

Proposed [GID-TA10694] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

Proposed [GID-TA10698] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etranacogene dezaparvovec for treating haemophilia B [ID3812]

Proposed [GID-TA10699] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

Proposed [GID-TA10702] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eptinezumab for preventing migraine [ID3803]

Proposed [GID-TA10677] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gefapixant for treating refractory chronic cough [ID3789]

Proposed [GID-TA10678] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for general anaesthesia [ID3796]

Proposed [GID-TA10679] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Proposed [GID-TA10680] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Proposed [GID-TA10682] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

Proposed [GID-TA10684] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

Proposed [GID-TA10683] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Proposed [GID-TA10723] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]

Proposed [GID-TA10725] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

Proposed [GID-TA10726] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]

Proposed [GID-TA10632] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Odevixibat (A 4250) for progressive familial intrahepatic cholestasis [ID1570]

Proposed [GID-TA10704] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Sotagliflozin for treating type 2 diabetes [ID1657]

Proposed [GID-TA10665] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

Proposed [GID-TA10598] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]

Proposed [GID-TA10739] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]

Proposed [GID-TA10706] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]

Proposed [GID-TA10701] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]

Proposed [GID-TA10654] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]

Proposed [GID-TA10714] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]

Proposed [GID-TA10727] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Proposed [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amivantamab for non-small cell lung cancer [ID3836]

Proposed [GID-TA10729] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Proposed [GID-TA10730] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Proposed [GID-TA10700] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]

Proposed [GID-TA10658] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Proposed [GID-TA10536] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Proposed [GID-TA10757] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Proposed [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Proposed [GID-TA10741] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

Proposed [GID-TA10666] Expected publication date: 26 August 2021

Type

Technology appraisal guidance

Status

Proposed
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]

Proposed [GID-TA10676] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Proposed [GID-TA10763] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Proposed [GID-TA10655] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

Proposed [GID-TA10764] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Liposomal bupivacaine for treating postoperative pain [ID3799]

Proposed [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Semaglutide for managing overweight and obesity [ID3850]

Proposed [GID-TA10765] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

Proposed [GID-TA10733] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]

Proposed [GID-TA10782] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Proposed [GID-TA10660] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Epilepsies in children, young people and adults

In development [GID-NG10112] Expected publication date: 16 November 2021

Type

NICE guideline

Status

In development
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

In development [GID-NG10110] Expected publication date: TBC

Type

NICE guideline

Status

In development
Stroke rehabilitation in adults

In development [GID-NG10175] Expected publication date: 14 December 2022

Type

NICE guideline

Status

In development
Postnatal care

In development [GID-NG10070] Expected publication date: 07 April 2021

Type

NICE guideline

Status

In development